Document Detail

Prehypertension: the rationale for early drug therapy.
MedLine Citation:
PMID:  20553286     Owner:  NLM     Status:  In-Process    
Blood pressure within prehypertensive levels confers higher cardiovascular risk by two means. At first, these levels are associated with higher risk for cardiovascular events, starting at BP values as low as 115/75 mmHg, and doubling at each 20 mmHg for systolic or 10 mmHg for diastolic BP. Prehypertension is also an intermediate stage for full hypertension, which develops in an annual rate of 7 out 100 individuals with 40-50 years of age. The precocious drug intervention in patients with prehypertension is therefore appealing. In individuals with previous cardiovascular disease or diabetes the use of BP-lowering agents is compulsory, since the 18-42% reduction of major cardiovascular events demonstrated in randomized clinical trials translates in palpable clinical benefit. In the absence of higher baseline risk, the absolute benefit of treatment is presumably small and was not demonstrated to date. These individuals could be candidate to treatment with the aim to prevent the development of full hypertension. The long-lasting effectiveness of non-drug therapies is low outside the controlled conditions of randomized clinical trials, and there are evidences that the use of BP-lowering drugs reduces the incidence of hypertension in individuals with prehypertension by more than 60%. Clinical trials testing the efficacy and safety of BP agents to prevent hypertension in a population-based perspective are required. In the meantime, it is worthy to present the option to start low doses of BP agents for individuals with prehypertension without co-morbidities who do not respond to the prescription of lifestyle modification.
Flávio Danni Fuchs
Related Documents :
16053966 - Prognosis of "masked" hypertension and "white-coat" hypertension detected by 24-h ambul...
17163276 - Relationship between the frequency of blood pressure self-measurement and blood pressur...
8817406 - Effects of moderate salt restriction alone and in combination with cilazapril on office...
20567256 - Effects of α-blocker 'add on' treatment on blood pressure in symptomatic bph with or w...
12668496 - Dysfunctional baroreflex regulation of sympathetic nerve activity in patients with vaso...
21752726 - Organ-specificity of placebo effects on blood pressure.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Cardiovascular therapeutics     Volume:  28     ISSN:  1755-5922     ISO Abbreviation:  Cardiovasc Ther     Publication Date:  2010 Dec 
Date Detail:
Created Date:  2010-11-05     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101319630     Medline TA:  Cardiovasc Ther     Country:  England    
Other Details:
Languages:  eng     Pagination:  339-43     Citation Subset:  IM    
Copyright Information:
© 2010 Blackwell Publishing Ltd.
Hospital de Clínicas de Porto Alegre, Serviço de Cardiologia, UFRGS, Porto Alegre-RS, Brazil.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Comment In:
Cardiovasc Ther. 2010 Dec;28(6):337-8   [PMID:  21050419 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Regression of cardiac valvulopathy related to ergot-derived dopamine agonists.
Next Document:  Cardiovascular implantable electronic devices in athletes.